Abstract
The placenta has traditionally been considered as a highly permeable organ for a large variety of substances with diverse molecular structures that are readily able to cross it from the maternal blood to reach the foetus. This has recommended limiting the use of drugs during pregnancy as far as possible. However, our present knowledge points to the existence of different systems, including plasma membrane carriers, biotransforming enzymes, and export pumps, that determine the selectivity and efficacy of the so-called placental barrier. A good understanding of the molecular bases of these processes and their regulation is crucial: i) to predict interactions between drug-drug, drug-endogenous substances and drug-food components, ii) to analyse the relevance of polymorphisms in the inter-individual variability of conceptus sensitivity to drugs, and iii) to develop novel pharmacological strategies aimed at delivering medicinal drugs to pregnant women, simultaneously minimising the risk of foetal exposure to active agents, and to specifically target drugs to the placenta and / or foetus. The present review does not attempt to offer a complete list of the available medicinal compounds and their ability to cross the placenta but instead to provide the reader with an up-to-date overview of the mechanisms involved in carrying out or preventing the transfer of active drugs across the placenta.
Keywords: placental barrier, plasma membrane carriers, biotransforming enzymes, export pumps
Current Drug Delivery
Title: A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs
Volume: 1 Issue: 3
Author(s): Jose J.G. Marin, Oscar Briz and Maria A. Serrano
Affiliation:
Keywords: placental barrier, plasma membrane carriers, biotransforming enzymes, export pumps
Abstract: The placenta has traditionally been considered as a highly permeable organ for a large variety of substances with diverse molecular structures that are readily able to cross it from the maternal blood to reach the foetus. This has recommended limiting the use of drugs during pregnancy as far as possible. However, our present knowledge points to the existence of different systems, including plasma membrane carriers, biotransforming enzymes, and export pumps, that determine the selectivity and efficacy of the so-called placental barrier. A good understanding of the molecular bases of these processes and their regulation is crucial: i) to predict interactions between drug-drug, drug-endogenous substances and drug-food components, ii) to analyse the relevance of polymorphisms in the inter-individual variability of conceptus sensitivity to drugs, and iii) to develop novel pharmacological strategies aimed at delivering medicinal drugs to pregnant women, simultaneously minimising the risk of foetal exposure to active agents, and to specifically target drugs to the placenta and / or foetus. The present review does not attempt to offer a complete list of the available medicinal compounds and their ability to cross the placenta but instead to provide the reader with an up-to-date overview of the mechanisms involved in carrying out or preventing the transfer of active drugs across the placenta.
Export Options
About this article
Cite this article as:
Marin J.G. Jose, Briz Oscar and Serrano A. Maria, A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs, Current Drug Delivery 2004; 1 (3) . https://dx.doi.org/10.2174/1567201043334731
DOI https://dx.doi.org/10.2174/1567201043334731 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Current Gene Therapy The use of Human Allogenic Graft (HBA) for Maxillary Bone Regeneration: Review of Literature and Case Reports
Current Pharmaceutical Design Genes Involved in Hereditary Hearing Impairment
Current Genomics Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Drugs, Environmental Factors, Loci and Genes Involved in Nonsyndromic Orofacial Cleft
Current Pharmacogenomics Patent Ductus Arteriosus in Extreme Prematurity: Role of Echocar-diography and Other Imaging Techniques
Current Pediatric Reviews Cardiac Innervation and Sudden Cardiac Death
Current Cardiology Reviews Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Identifying New Pathways and Targets for Wound Healing and Therapeutics from Natural Sources
Current Drug Delivery Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms Involved in the Progression and Protection of Osteoarthritis
Current Molecular Pharmacology Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews